Ra Capital Management, L.P. Viridian Therapeutics, Inc.\De Transaction History

Ra Capital Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$25.04 - $37.6 $28.2 Million - $42.4 Million	1,127,946 Added 128.18%	2,007,946 $51.1 Million
Q3 2022 Nov 14, 2022	BUY	$10.7 - $25.5 $9.42 Million - $22.4 Million	880,000 New	880,000 $18 Million
Q4 2021 Feb 14, 2022	SELL	$15.65 - $21.5 $16,182 - $22,231	-1,034 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$10.69 - $18.2 $3.33 Million - $5.67 Million	-311,294 Reduced 99.67%	1,034 $17,000
Q1 2021 May 17, 2021	BUY	$15.5 - $24.93 $4.84 Million - $7.79 Million	312,328 New	312,328 $5.22 Million

181

76.7M

581K

439K

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $795M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Ra Capital Management, L.P. with notifications on news.